These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30427309)

  • 21. Immunopathology of Pulmonary
    Kolloli A; Kumar R; Venketaraman V; Subbian S
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spatial multiomic profiling reveals the novel polarization of foamy macrophages within necrotic granulomatous lesions developed in lungs of C3HeB/FeJ mice infected with
    Seto S; Nakamura H; Guo TC; Hikichi H; Wakabayashi K; Miyabayashi A; Nagata T; Hijikata M; Keicho N
    Front Cell Infect Microbiol; 2022; 12():968543. PubMed ID: 36237431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoroquinolone derivatives and their anti-tubercular activities.
    Fan YL; Wu JB; Cheng XW; Zhang FZ; Feng LS
    Eur J Med Chem; 2018 Feb; 146():554-563. PubMed ID: 29407980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.
    Sarathy JP; Via LE; Weiner D; Blanc L; Boshoff H; Eugenin EA; Barry CE; Dartois VA
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One Size Fits All? Not in
    Yang HJ; Wang D; Wen X; Weiner DM; Via LE
    Front Cell Infect Microbiol; 2021; 11():613149. PubMed ID: 33796474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluoroquinolones for the treatment of tuberculosis in children.
    Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
    Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On-Slide Heat Sterilization Enables Mass Spectrometry Imaging of Tissue Infected with High-Threat Pathogens Outside of Biocontainment: A Study Directed at
    Wang N; Sarathy JP; Zimmerman M; Kaya F; Wang H; Dartois V; Carter CL
    J Am Soc Mass Spectrom; 2021 Nov; 32(11):2664-2674. PubMed ID: 34672552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.
    Ahmad Z; Fraig MM; Pinn ML; Tyagi S; Nuermberger EL; Grosset JH; Karakousis PC
    J Antimicrob Chemother; 2011 Jul; 66(7):1560-6. PubMed ID: 21602551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy.
    Zimmerman M; Lestner J; Prideaux B; O'Brien P; Dias-Freedman I; Chen C; Dietzold J; Daudelin I; Kaya F; Blanc L; Chen PY; Park S; Salgame P; Sarathy J; Dartois V
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.
    Pranger AD; Alffenaar JW; Aarnoutse RE
    Curr Pharm Des; 2011; 17(27):2900-30. PubMed ID: 21834759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies.
    Kramnik I; Beamer G
    Semin Immunopathol; 2016 Mar; 38(2):221-37. PubMed ID: 26542392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis.
    Sarathy J; Dartois V; Dick T; Gengenbacher M
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1648-53. PubMed ID: 23335744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions.
    Sarathy JP; Liang HH; Weiner D; Gonzales J; Via LE; Dartois V
    J Vis Exp; 2017 May; (123):. PubMed ID: 28518128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
    Shandil RK; Jayaram R; Kaur P; Gaonkar S; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Balasubramanian V
    Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry (LCM-LC/MS).
    Zimmerman M; Blanc L; Chen PY; Dartois V; Prideaux B
    J Vis Exp; 2018 Apr; (134):. PubMed ID: 29733325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Something Old, Something New: Ion Channel Blockers as Potential Anti-Tuberculosis Agents.
    Mitini-Nkhoma SC; Chimbayo ET; Mzinza DT; Mhango DV; Chirambo AP; Mandalasi C; Lakudzala AE; Tembo DL; Jambo KC; Mwandumba HC
    Front Immunol; 2021; 12():665785. PubMed ID: 34248944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An adjunctive therapeutic vaccine against reactivation and post-treatment relapse tuberculosis.
    Miyata T; Cheigh CI; Casali N; Goodridge A; Marjanovic O; Kendall LV; Riley LW
    Vaccine; 2012 Jan; 30(2):459-65. PubMed ID: 22079078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoroquinolones and tuberculosis.
    Bryskier A; Lowther J
    Expert Opin Investig Drugs; 2002 Feb; 11(2):233-58. PubMed ID: 11829714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.